Advertisement

Advances and challenges in translating stem cell therapies for clinical diseases

  • Michael A. Matthay
    Correspondence
    Reprint requests: Michael A. Matthay, MD, Cardiovascular Research Institute, University of California San Francisco, 505 Parnassus Ave, M-917, San Francisco, CA 94143-0624
    Affiliations
    Institute at the University of California, San Francisco, Calif
    Search for articles by this author
Published:August 05, 2010DOI:https://doi.org/10.1016/j.trsl.2010.07.007
      In this special issue of Translational Research, several articles consider the potential of harnessing stem cells for therapy of human diseases. This topic is large in a field that is evolving rapidly. Several different candidate stem cells include embryonic stem cells, induced pluripotent stem cells, endothelial progenitor cells, and mesenchymal stem cells. Common themes include the nature and location of endogenous stem cells, preclinical evidence supporting the potential therapeutic use of stem cells for acute and chronic diseases, the challenges in translating the preclinical work to clinical applications, as well as the results of a few randomized clinical trials.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Translational Research
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Alaiti M.A.
        • Ishikawa M.
        • Costa M.A.
        Bone marrow and circulating stem/progenitor cells for regenerative cardiovascular therapy.
        Trans Res. 2010; 156: 112-129
        • Lee R.H.
        • Pulin A.A.
        • Seo M.J.
        • et al.
        Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6.
        Cell Stem Cell. 2009; 5 (54–3)
        • Hare J.M.
        • Traverse J.H.
        • Henry T.D.
        • et al.
        A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction.
        J Am Coll Cardiol. 2009; 54 (2277–6)
        • Lionetti V.
        • Recchia F.A.
        New therapies for the failing heart: trans-genes versus trans-cells.
        Trans Res. 2010; 156: 130-135
        • Pino C.J.
        • Humes H.D.
        Stem cell technology for the treatment of acute and chronic renal failure.
        Trans Res. 2010; 156: 161-168
        • Bruno S.
        • Grange C.
        • Deregibus M.C.
        • et al.
        Mesenchymal stem cell-derived microvesicles protect against acute tubular injury.
        J Am Soc Nephrol. 2009; 20: 1053-1067
        • Schwartz S.C.
        • Schwarz J.
        Translation of stem cell therapy for neurological diseases.
        Trans Res. 2010; 156: 155-160
        • Shaker A.
        • Ruben D.C.
        Intestinal stem cells and epithelial-mesenchymal interactions in the crypt and stem cell niche.
        Trans Res. 2010; 156: 179-186
        • Sueblinvong V.
        • Weiss D.J.
        Stem cells and cell therapy approaches in lung biology and diseases.
        Trans Res. 2010; 156: 187-204
        • Lee J.W.
        • Fang X.
        • Gupta N.
        • Serikov V.
        • Matthay M.A.
        Allogeneic human mesenchymal stem cells for treatment of E. coli endotoxin-induced acute lung injury in the ex vivo perfused human lung.
        Proc Natl Acad Sci U S A. 2009; 106: 16357-16362
        • Nemeth K.
        • Leelahavanichkul A.
        • Yuen P.S.
        • et al.
        Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production.
        Nat Med. 2009; 15: 42-49
        • Mei S.H.
        • Haitsma J.J.
        • Dos Santos C.C.
        • et al.
        Mesenchymal stem cells reduce inflammation while enhancing bacterial clearance and improving survival in sepsis.
        Am J Respir Crit Care Med. 2010;
        • Ortiz L.A.
        • Dutreil M.
        • Fattman C.
        • et al.
        Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury.
        Proc Natl Acad Sci U S A. 2007; 104: 11002-11007
        • Dudek A.Z.
        Endothelial lineage cell as a vehicle for systemic delivery of cancer gene therapy.
        Trans Res. 2010; 156: 136-146
        • Knorr D.A.
        • Kaufman D.S.
        Pluripotent stem cell-derived natural killer cells for cancer therapy.
        Trans Res. 2010; 156: 147-154
        • Wagner R.T.
        • Lewis J.
        • Cooney A.
        • Chan L.
        Stem cell approaches for the treatment of type 1 diabetes mellitus.
        Trans Res. 2010; 156: 169-178